LENZ Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

6.060

Open

5.610

VWAP

5.85

Vol

828.44K

Mkt Cap

184.68M

Low

5.495

Amount

4.85M

EV/EBITDA(TTM)

Total Shares

31.35M

-73.71M

EV/OCF(TTM)

P/S(TTM)

LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

Events Timeline

(ET)

2026-05-12

09:40:00

LENZ Therapeutics Trading Halted

2026-05-11 (ET)

2026-05-11

19:40:00

Energy and Basic Materials Propel S&P 500 to Record Highs

News

8.5

07-06Newsfilter

PinnedLENZ Launches Telehealth Platform for VIZZ

7.5

06-24Newsfilter

LENZ and Arrotex Sign Exclusive License Agreement for VIZZ in Australia and New Zealand

8.5

06-12NASDAQ.COM

Biotech Sector Sees Surge in FDA and Global Approvals

7.5

06-08NASDAQ.COM

LENZ Partners with Everest for VIZZ Development in Greater China

8.5

06-08seekingalpha

LENZ and Everest Medicines Sign Asset Purchase Agreement for VIZZ® in Greater China

8.5

06-07Newsfilter

LENZ and Everest Enter Asset Purchase Agreement for VIZZ in Greater China

5 Analyst Rating

Wall Street analysts forecast LENZ stock price to rise

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

52.00

Averages

57.50

High

62.00

Current: 0.000

Low

52.00

Averages

57.50

High

62.00

Citi

Buy

downgrade

$26 -> $20

AI Analysis

2026-05-13

Reason

Citi

Price Target

$26 -> $20

AI Analysis

2026-05-13

downgrade

Buy

Reason

Citi lowered the firm's price target on Lenz Therapeutics to $20 from $26 and keeps a Buy rating on the shares.

BofA

Buy

maintain

$29 -> $31

2026-05-12

Reason

BofA

Price Target

$29 -> $31

2026-05-12

maintain

Buy

Reason

BofA raised the firm's price target on Lenz Therapeutics to $31 from $29 and keeps a Buy rating on the shares. The firm remains "optimistic" on VIZZ launch efforts following the company's Q1 update, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LENZ

Unlock Now

Valuation Metrics

The current forward P/E ratio for LENZ Therapeutics Inc (LENZ.O) is 0.00, compared to its 5-year average forward P/E of -10.36. For a more detailed relative valuation and DCF analysis to assess LENZ Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.36

Current PE

0.00

Overvalued PE

-7.98

Undervalued PE

-12.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.60

Current EV/EBITDA

-0.11

Overvalued EV/EBITDA

-2.39

Undervalued EV/EBITDA

-10.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

39.40

Current PS

2.86

Overvalued PS

84.30

Undervalued PS

-5.49

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

low float high volume medical stock

Intellectia · 22 candidates

Sector: Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical ResearchVolume: >= 1,000,000List Exchange: XNYS, XNAS, XASEFloating Shares: <= 30,000,000

Ticker

Name

Market Cap$

AKAN

Akanda Corp

1.66M

IBIO

iBio Inc

60.11M

BIAF

bioAffinity Technologies Inc

21.32M

AZTR

Azitra Inc

3.82M

KPTI

Karyopharm Therapeutics Inc

109.27M

SNGX

Soligenix Inc

12.20M

stocks that are bearish tmr

Intellectia · 29 candidates

Rsi Category: moderateMoving Average Relationship: PriceBelowMA20Week Price Change Pct: <= $-2.00One Day Rise Prob: <= 45One Day Predict Return: <= -0.5%

Ticker

Name

Market Cap$

HELE

Helen of Troy Ltd

408.84M

AUUD

Auddia Inc

2.28M

NOC

Northrop Grumman Corp

96.34B

FCAP

First Capital Inc

176.65M

SKIL

Skillsoft Corp

56.49M

CRD.B

Crawford & Co

505.39M

welche Aktien sollte ich morgen kaufen?

Intellectia · 21 candidates

Relative Vol: >= 1Rsi 14: 20 - 85Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $0.00Is Trending: True

Ticker

Name

Market Cap$

LLY

Eli Lilly and Co

1.02T

FCX

Freeport-McMoRan Inc

86.99B

CCJ

Cameco Corp

53.26B

FERG

Ferguson Enterprises Inc

48.76B

CRWV

CoreWeave Inc

46.87B

ALAB

Astera Labs Inc

29.73B

stocks to buy with strong short term gains

Intellectia · 16 candidates

Relative Vol: >= 0.900Rsi 14: 30 - 75Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $0.50Is Trending: True

Ticker

Name

Market Cap$

FERG

Ferguson Enterprises Inc

48.76B

CRWV

CoreWeave Inc

46.87B

ALAB

Astera Labs Inc

29.73B

EXE

Expand Energy Corp

26.08B

Fabrinet

17.50B

FIGR

Figure Technology Solutions Inc

14.71B

what stocks will i gain on today

Intellectia · 20 candidates

Relative Vol: >= 1.20Moving Average Relationship: PriceAboveMA5Month Price Change Pct: >= $0.00Is Trending: True

Ticker

Name

Market Cap$

LLY

Eli Lilly and Co

1.02T

FCX

Freeport-McMoRan Inc

86.99B

CCJ

Cameco Corp

53.26B

EXE

Expand Energy Corp

26.08B

MRNA

Moderna Inc

19.46B

Fabrinet

17.50B

which stcok could go higher this week ?

Intellectia · 20 candidates

Relative Vol: >= 1.20Moving Average Relationship: PriceAboveMA5Week Price Change Pct: >= $0.00Is Trending: True

Ticker

Name

Market Cap$

LLY

Eli Lilly and Co

1.02T

FCX

Freeport-McMoRan Inc

86.99B

ABNB

Airbnb Inc

81.00B

CCJ

Cameco Corp

53.26B

EXE

Expand Energy Corp

26.08B

MRNA

Moderna Inc

19.46B

pik ot day

Intellectia · 21 candidates

Market Cap: >= 300.00MRelative Vol: >= 1.10Week Price Change Pct: >= $0.00Is Trending: True

Ticker

Name

Market Cap$

LLY

Eli Lilly and Co

1.02T

FCX

Freeport-McMoRan Inc

86.99B

ABNB

Airbnb Inc

81.00B

CCJ

Cameco Corp

53.26B

CRWV

CoreWeave Inc

46.87B

ALAB

Astera Labs Inc

29.73B

what stock will grow next week

Intellectia · 12 candidates

Relative Vol: >= 1.10Week Price Change Pct: >= $0.00Is Trending: True

Ticker

Name

Market Cap$

LLY

Eli Lilly and Co

1.02T

ABNB

Airbnb Inc

81.00B

MRNA

Moderna Inc

19.46B

Fabrinet

17.50B

GPCR

Structure Therapeutics Inc

6.48B

LMND

Lemonade Inc

6.38B

top 10 stocks to daytrade today

Intellectia · 10 candidates

Relative Vol: >= 1.20Weekly Average Turnover: >= 1,000,000Rsi 14: 20 - 80Week Price Change Pct: >= $3.00Is Trending: True

Ticker

Name

Market Cap$

CRWV

CoreWeave Inc

46.87B

EXE

Expand Energy Corp

26.08B

LMND

Lemonade Inc

6.38B

TMC

TMC the metals company Inc

3.38B

LPTH

LightPath Technologies Inc

726.74M

enCore Energy Corp

610.54M

good quick money any stocks worth my look

Intellectia · 20 candidates

Relative Vol: >= 1.20Rsi 14: 20 - 80Week Price Change Pct: >= $0.00Is Trending: True

Ticker

Name

Market Cap$

LLY

Eli Lilly and Co

1.02T

FCX

Freeport-McMoRan Inc

86.99B

ABNB

Airbnb Inc

81.00B

CRWV

CoreWeave Inc

46.87B

ALAB

Astera Labs Inc

29.73B

EXE

Expand Energy Corp

26.08B

Whales Holding LENZ

RA Capital Management, L.P.

Tang Capital Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is LENZ Therapeutics Inc (LENZ) stock price today?

The current price of LENZ is 6.005 USD — it has increased 7.23

What is LENZ Therapeutics Inc (LENZ)'s business?

What is the price predicton of LENZ Stock?

Wall Street analysts forecast LENZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LENZ is57.50 USD with a low forecast of 52.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.